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Background: Small viral reservoirs are found predominantly in HIV-1 controllers and individuals treated dur-
ing acute/early HIV-1 infection. However, other HIV+ individuals could naturally also harbour low viral
reservoirs.
Methods: We screened 451 HIV-1-infected treated-individuals with suppressed plasma viremia for at least
3 years and stored cryopreserved peripheral blood mononuclear cells (PBMCs). Total HIV-DNA was analysed
in PBMCs with ddPCR. Individuals with <50 HIV-DNA copies/106 PBMCs constitute the ‘Low Viral Reservoir
Treated’ cohort (LoViReT). Longitudinal samples were obtained from 12 chronically treated LoViReT and
compared to 13 controls (>50 HIV-DNA copies/106 PBMCs) to analyse total HIV-DNA, T-cell and NK-cell pop-
ulations, HIV-1 specific antibodies, and plasma inflammation markers.
Findings: We found that 9.3% of the individuals screened had <50 HIV-DNA copies/106 PBMCs. At least 66%
initiated cART during the chronic phase of HIV-1 infection (cp-LoViReT). Cp-LoViReT harboured lower levels
of HIV-DNA before cART and after treatment introduction the decays were greater compared to controls.
They displayed a marked decline in quantity and avidity in HIV-specific antibodies after initiation of cART.
Cp-LoViReT had fewer CD8+ TTM and TEMRA in the absence of cART, and higher CD8+ TN after 18 months on
therapy.
Interpretation: Treated chronically HIV-1-infected LoViReT represent a new phenotype of individuals charac-
terized by an intrinsically reduced viral reservoir, less impaired CD8+ T-cell compartment before cART, and
low circulating HIV-1 antigens despite being treated in the chronic phase of infection. The identification of
this unique group of individuals is of great interest for the design of future eradication studies.
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The implementation of combination antiretroviral therapy
(cART) to treat HIV-1 infection has substantially improved the life
PANEL 1: RESEARCH IN CONTEXT
Evidence before this study
We searched PubMed using the terms “HIV reservoir”, “HIV
DNA”, or “HIV latency”, and “low”, with no restrictions by date
or language, for studies that assess HIV-1-infected individuals
with a very low reservoir. We found evidence of low viral reser-
voirs, mostly in individuals treated during acute/early infection,
elite controllers and post-treatment controllers. However, we
also found 4 studies that described treated chronically infected
individuals with a low HIV reservoir and correlated low viral
reservoirs with clinical parameters and/or viral rebound if ther-
apy is interrupted.
Added value of this study
We demonstrate that 9% of HIV-1-infected individuals can har-
bour low levels of HIV-DNA (LoViReT individuals), with 66% of
them treated during the chronic phase of infection. Ours is the
first study to assess the kinetics of reservoirs in chronically
HIV-1-infected individuals harbouring low levels of total HIV-1
DNA. We found a combination of intrinsically low reservoir
with enhanced decay of latency after initiation of treatment. In
addition, the LoViReT individuals had a less impaired CD8+ T
compartment before initiation of treatment and lower amounts
of circulating antigens after 5 years on treatment.
Implications of all the available evidence
Our results reveal a novel phenotype of chronically treated
individuals characterized by a naturally reduced and more
ART-sensitive viral reservoir. Therefore, LoViReT individuals are
of particular interest when designing approaches to eradicate
HIV, since their smaller reservoir and other characteristics
might represent an advantage over individuals with a larger
reservoir. Further studies on the host and viral parameters of
these individuals are warranted to identify factors that are
potentially involved in these phenomena. Such studies should
contribute to the development of more rational HIV remission
strategies based on novel concepts.
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completely eliminate HIV-1, which persists as a latent infection
mainly in resting CD4+ T cells, thus leading to rapid relapse of viremia
if therapy is interrupted [1]. Consequently, there is emerging interest
in developing safe and affordable curative strategies to eliminate the
need for lifelong therapy while improving the health of people living
with HIV and reducing the risk of viral transmission to uninfected
individuals [24].
A wide variety of strategies currently focus on eradicating HIV-1
with the aim of reducing the latent viral reservoir to undetectable
levels [5]. Therefore, factors related to the size, distribution, and sta-
bility of the viral reservoir are continuously being investigated. It has
been postulated that the amount of HIV-1 DNA is a predictor of dis-
ease progression in primary infection [6] and during the natural
course of HIV-1 infection [7]. Lower levels of HIV-1 DNA have been
observed, mostly in elite controllers, who spontaneously control viral
replication [8], as well as in post-treatment controllers [9], and allo-
geneic stem cell transplant recipients [1013].
Various studies suggest that early initiation of cART is an impor-
tant factor in reducing the size of the viral reservoir [14,15], espe-
cially if initiated at Fiebig stage I [16]. Unfortunately, individuals are
rarely treated during the acute phase, since most new diagnoses ofHIV-1 infection are made at the chronic stage, when the reservoirs
are more stable [17]. Eradication strategies need to be effective in the
vast majority of treated chronically HIV-1-infected individuals. Sev-
eral studies have described treated chronically infected individuals
with low or even undetectable levels of total HIV-1 DNA [1820].
However, no retrospective data have been reported on the joint pro-
portion of individuals who achieve a low reservoir after initiation of
treatment in both the acute and the chronic phases. Furthermore, the
factors involved in achieving these low latency levels have not been
investigated in depth.
In this study, we screened the total HIV-1 DNA reservoir in 451
treated HIV-1-infected individuals with suppressed plasma viremia
for at least 3 years and stored cryopreserved peripheral blood mono-
nuclear cells (PBMCs) to establish the Low Viral Reservoir Treated
cohort (LoViReT). We aimed to study the kinetics of these decreased
reservoirs and to analyse associated clinical and immunological fac-
tors. To do so, we focused on a subset of LoViReT individuals who ini-
tiated treatment in the chronic phase of the infection (cp-LoViReT) in
order to identify strategies that could be applied in the vast majority
of treated HIV-1-infected individuals.
2. Methods
2.1. Study participants
We retrospectively screened 451 HIV-1-infected subjects under-
going regular follow-up at Hospital Germans Trias i Pujol (n=319)
and Hospital Clinic (n=132) in Barcelona. We included individuals
under suppressive cART with undetectable viremia (HIV-RNA <50
copies/ml) for at least 3 years and with available cryopreserved
PBMCs. Demographic and clinical data were collected from the clini-
cal database. The characteristics of the study participants were simi-
lar to those of previously reported cohorts of individuals with low
HIV reservoirs in terms of sex, age, and time with infection [1820].
Treated chronically infected participants were defined as individuals
with more than 6 months between acquisition of HIV-1 and initiation
of treatment. All subjects provided their signed informed consent to
participate in the study. The study was approved by the Ethics Com-
mittee at both recruiting hospitals (reference #: PI-014-083).
2.2. Quantification of proviral HIV-1 DNA
The size of the proviral reservoir was measured in PBMCs for
screening and in purified CD4+ peripheral T cells for the longitudinal
analysis (Miltenyi Biotech) by droplet digital polymerase chain reac-
tion (ddPCR), as previously reported, without modifications [21].
Cells were resuspended in lysis buffer at a concentration of 5 £ 104
cells/ml, which consisted of UltraPure DNAse-RNAsefree water
(Gibco, Invitrogen) containing 10 mM Tris-HCl (pH=90), 01% Triton
x-100 (Sigma), and 400 mg/ml Proteinase K (Ambion). Two different
primer sets per subject (50LTR and Gag [21]) were used to circumvent
potential mismatches in the viral sequences that could prevent effi-
cient amplification. In addition, the RPP30 [21] housekeeping gene
was measured in parallel to normalize sample input. PBMCs from
HIV-negative donors were used as negative controls and assayed in
each plate to set the positive/negative threshold. The number of
those negative control wells was the same as that of the replicates for
each sample. Raw ddPCR data were analysed using the QX100TM
Droplet Reader and the software application QuantaSoft v.1.6 (Bio-
Rad, Hercules, CA, USA).
2.3. Viral tropism
Viral coreceptor tropism was determined on proviral DNA by
sequencing of HIV-1 gp120 hypervariable region 3 (V3). Tropism was
predicted using the Geno2Pheno algorithm (GENAFOR, Bonn,
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FPR 10%) [22].2.4. Immunophenotyping and activation markers in peripheral CD4+,
CD8+, and NK cells
For T-cell immunophenotyping, cells were incubated with Fixable
Viability Stain 780 (APC H7), CD3 (SK7), CD4 (RPA-T4), and CD8 (SK1)
monoclonal antibodies. T-cell maturation was based on the expres-
sion of CD45RA (HI100), and CD197/CCR7 (G043H7) was analysed in
cryopreserved PBMCs in order to define naïve (CD45RA+CCR7+, TN),
central memory (CD45RACCR7+, TCM), effector (CD45RACCR7,
TEF), and effector memory RA+ cells (CD45RA+CCR7, TEMRA). CD27
(O323) was used to differentiate effector cells into effector memory
cells (CD27CD4+ or CD27+CD8+, TEM), and transitional memory cells
(CD27+CD4+ or CD27CD8+, TTM). CD4 and CD8 T cells were also ana-
lysed for expression of HLA-DR (L243) and CD38 (HIT2) to define acti-
vated cells (HLA-DR+CD38+); expression of CD279/PD-1 (EG12.2H7)
was analysed to measure exhausted cells (CD279+). TIM-3 (F38-2E2),
LAG-3 (11C3C65), CD32 (FUN-2), and CD2 (RPA-2.10) markers were
also measured in CD4+ T cells as potential surrogate markers of the
viral reservoir through analysis of CD4+TIM-3+ CD4+LAG3+,
CD4+CD32+, CD4+CD32bright (to avoid potential B-cell contamination),
and CD4+CD2bright cells. The gating strategy is shown in Suppl. Fig. 2.
For NK immunophenotyping, cells were incubated with the
appropriate monoclonal antibodies and Zombie AquaTM for 30 min at
4°C, washed, and fixed with 4% PFA. The following monoclonal anti-
bodies were used for surface staining: CD3 (UCHT1), CD14 (M5E2),
and CD19 (SJ25C1) for the lineage negative cells and CD45 (HI30),
CD16 (3G8), CD56 (NCAM16.2), CD69 (FN50), NKp46/CD335 (9E2),
NKP30/CD337 (AF29-4D12), NKG2A/CD159a (REA110), NKG2C/
CD159c (134591), NKB1 (DX9), KIR2D/CD158a (NKVFS1), KIR3DL1/
DL2/CD158e/k (REA970), CD161(DX12), and CXCR5/CD185 (MU5U-
BEE) for NK cell phenotyping as previously reported [23].
Samples were acquired in a BD LSRFortessa or LSRII flow cytome-
ter (BD Bioscience) and analysed using FlowJo software (Tree Star). T
cells were analysed with automated detection of marker cutoffs
based on fluorescence-minus-one controls (OurFlow platform using
R packages).2.5. Viral inhibition by CD8+ T and NK cells
PBMCs were thawed and cultured overnight in RPMI 1640 con-
taining GlutaMAX, 20% FCS, penicillin (10 IU/ml), and streptomycin
(10 mg/ml). Analyses were performed as previously described [24].
Briefly, CD4+ T cells were purified by positive selection with anti-
body-coated magnetic beads (EasySep Human CD4 Positive Selection,
StemCell Technologies). The elution containing CD4-depleted PBMCs
was split and used for purification of CD8+ T-cells and NK cells by
negative selection (EasySep Human CD8+ Cell Enrichment, EasySep
Human NK Enrichment, StemCell Tecnhologies). Cells were separated
using a RoboSep instrument (Stemcell Technology).
CD4+ T cells were activated for 3 days in the presence of 4 mg/ml
PHA-L (Roche) and 100 IU/ml IL-2 (Human IL-2 IS, premium grade,
Miltenyi Biotech). During this period, NK cells were cultured in the
presence of IL-15 at 01 ng/ml and CD8+ T cells in the absence of cyto-
kines. After 3 days of culture, living activated CD4+ T cells were
seeded in a 96-U-well plate (106 cells/ml in triplicate) alone or in the
presence of CD8+ T cells or NK cells (1:1 ratio) and then exposed to
HIV-1 BaL (CCR5 tropic strain) (10 ng p24/ml). After spinoculation
(1200 x g for 1 h at room temperature), cells were cultured for 1 h at
37°C and washed before culture in the presence of IL-2 (100 IU/ml).
Culture supernatants were removed, and the media culture was
replenished at day 3. Levels of p24 in culture supernatants were ana-
lysed at day 3 after infection for co-culture with NK cells and at day 7after infection for co-cultures with CD8+ T-cells using an ELISA p24
assay (HIV-1 p24 ELISA kit, XpressBio).
2.6. Quantification of inflammation biomarkers
Concentrations of the pro-inflammatory or homeostatic cytokines
IL-2, IL-6, IL-7, IL-10, IL-27, and IP10, as well as the coagulation bio-
marker D-dimer, were quantified in plasma using a bead-based mul-
tiplex immunoassay (ProcartaPlex, eBioscience) according to the
manufacturer’s recommendations. Measurements were performed
using a Luminex 100 instrument (Luminex Corp., Austin, TX, USA)
and analysed using a standard curve for each cytokine.
2.7. HIV antibody quantification
Specific HIV-1 antibodies were measured in plasma samples using
the HIV-1/2 VITROS assay (Ortho Clinical Diagnostics, Rochester, NY,
USA), a low sensitive (LS) version of the VITROS anti-HIV-1 assay, and
a limiting antigen avidity assay (Lag-Avidity) (Sedia, Portland, OR,
USA), as previously described [25].
2.8. Statistical analysis
The clinical characteristics of the study population were presented
as percentages for categorical variables and as median and interquar-
tile range (IQR) for continuous variables. The association between
clinical parameters with low levels of cell-associated total HIV-1 DNA
were analysed using univariate and multivariate logistic regression
models; the odds ratio (OR), p-value, and C-index are reported. Varia-
bles associated with the LoViReT status (p<01) were considered
candidates for the final model. The multivariate model was built
using a stepwise procedure and by selecting the variables associated
with LoViReT. The parameters assessed include gender, age at diag-
nosis, mode of infection, AIDS events, maximum viral load reported,
CD4 nadir, time since HIV-1 diagnosis, viral blips (<500 copies/ml),
detectable plasma viral load (pVL; any value above limit of detection),
time with detectable pVL, tropism, and the accumulated pVL score
calculated as the area of the positive pVL plot over time and normal-
ized (divided) by the follow-up time. The model was validated inter-
nally using a 10fold crossvalidation, and predictive ability was
assessed using the C-index (equivalent to the AUC under the ROC
curve).
In the longitudinal analysis, clinical differences between groups
were assessed using the Mann-Whitney test in the case of continuous
variables and the Fisher exact test in the case of categorical variables.
Clinical variables were matched between LoViReT subjects and con-
trols using the random forest algorithm in order to avoid confound-
ing factors associated with low HIV-1 DNA levels. Random forest [26]
is a popular machine learning algorithm based on ensembles of Clas-
sification and Regression Trees (CART) algorithm (regression and
classification trees), which provide good predictive performance and
low overfitting. In addition to the prediction model, the algorithm
provides a proximity measure matrix between observations that can
be used in matching [27]. In order to produce balanced treatment
and control groups in terms of all relevant clinical factors, we selected
a set of controls based on the RF proximity measure. Differences
within groups were assessed using the Wilcoxon signed-rank test.
The analyses were performed with R (v3.4) and GraphPad (v5.01).
3. Results
3.1. Characteristics of the screening population
TaggedPWe analysed samples from 451 individuals with more than 3 years
under suppressive cART (Suppl. Fig. 1). Their characteristics are sum-
marized in Table 1. Log10 proviral HIV-1 DNA in PBMCs was normally
Table 1
Clinical characteristics of the subjects included in the study
Characteristic N (%) Median [IQR]















Zenith viral load (log10 copies/ml plasma) 49 [43-53]
CD4 nadir (cells/ml) 273 [159-358]
Time since HIV diagnosis (years) 13 [7-19]
Viral blips 0 [0-1]
Virological failures 0 [0-2]
Tropism
R5-tropic 329 (73)




Total HIV-1 DNA (copies/106 PBMCs) 1585 [787-3134]
At the time of HIV-1 DNAmeasurements
Age 46 [41-51]
Time suppressed (years) 56 [4-8]
CD4 T cells (cells/ml) 676 [495-891]
CD8 T cells (cells/ml) 766 [567-1022]
CD4/CD8 ratio 0.9 [06-12]
4 C. Galvez et al. / EBioMedicine 57 (2020) 102830distributed (Fig. 1a). Median HIV-1 DNA was 1585 copies/106 PBMCs
(IQR, 79-313).
A total of 42 individuals were under the 10th percentile (<50 HIV-
1 DNA copies/106 PBMC) (93%), including 4 (09%) who had levels
below the limit of detection for the 2 sets of primers used. They wereFig. 1. Total HIV-1 DNA.
(a) Total HIV-1 DNA of 451 individuals after screening with ddPCR. Subjects with<50 cop
between the 2 recruiting centres. Subjects with <50 copies/106 PBMCs are shown in blue an
figure legend, the reader is referred to the web version of this article.).all included in the “LoViReT” (Low Viral Reservoir Treated Individu-
als) Cohort. The distribution of total HIV-1 DNA and proportion of
LoViReT individuals were similar between the 2 recruiting centres
(Fig. 1b). The clinical histories of LoViReT subjects confirmed that 28
individuals were treated in the chronic phase of the infection (>6
months since acquisition) and were defined as chronic phase LoViReT
subjects (cp-LoViReT). Out of the remaining LoViReT subjects, 6 were
treated in the acute stage, and 8 lacked proven information of their
time with infection at initiation of cART (Suppl. Fig. 1).
3.2. Factors related to LoViReT status
Clinical, immunological, and virological data were collected to
search for factors predicting whether the subject would belong to the
LoViReT cohort (Table 2).
In the univariate analysis, being in the LoViReT cohort was associ-
ated with a lower maximal reported pVL (p=00065), higher CD4+ T-
cell nadir (p=0002), lower number of viral blips (p=008), fewer
detectable pVLs defined as any pVL >50 copies/ml (p=00021), and
lower time with detectable pVL (p=00078) (Table 2). In the multivar-
iate regression model, only a lower maximal reported pVL, higher
CD4+ nadir, and fewer detectable pVLs remained significantly associ-
ated with LoViReT status (Table 2). Using the c-index method to eval-
uate the predictive capacity of the multivariate model, we observed a
goodness of fit of 072 after cross-validation. This is considered a
moderate predictive capacity.
Thus, LoViReT individuals seemed to have lower peaks of pVL, a
higher CD4+ T-cell nadir, and fewer detectable pVLs during their clini-
cal follow-up. However, this multivariate model had limited predic-
tive capacity.
Longitudinal analysis of HIV-1 DNA reservoirs: For further analy-
ses, we focused on the cp-LoViReT population, since this cohort is
less well characterized (Suppl. Fig.1). Thus, we aimed to unravel
whether the cp-LoViReT reservoir decreased as a consequence of
cART or whether these subjects had lower reservoirs before initia-
tion of cART. According to sample availability, we selected a sub-
group of 12 cp-LoViReT and compared them with 13 treated
chronically infected matched controls (>50 HIV-1 DNA copies/106
PBMCs) to perform a retrospective longitudinal reservoir analysis inies/106 PBMCs are shown in light blue. (b) Comparative distribution of total HIV-1 DNA
d red respectively to the each site. (For interpretation of the references to color in this
Table 2
Clinical associations with low levels of total HIV-1 DNA (LoViReT status)
Clinical variables Univariate Multivariate
OR [95% CI] p-value& OR [95% CI] p-value&
Gender (Male) 0981
Age at diagnosis 0642
Mode of infection 0782
AIDS events 0749
Maximum viral load reported log10 067 [051-089] 0007 066 [049-089] 00069
CD4 nadir (multiples of 100) 147 [120-181] <0001 146 [119-181] 00003
Time since HIV diagnosis 0177
Viral blips (<500 copies/ml) 064 [034-105] 0083
Detectable pVL (>50 copies/ml) 072 [055-090] 0002 079 [060-098] 00286
Time with detectable pVL (years) 076 [058-094] 0008
Tropism 0394
Accumulated viral load score 078 [062-095] 0.013
At the time of HIV-1 DNAmeasurements
Age 0531
Time suppressed (years) 0902
CD4 T cells (multiples of 100) 0648
CD8 T cells (multiples of 100) 0246
% CD4 T cells 0344
% CD8 T cells 0262
CD4/CD8 ratio 0217
& p-values based on likelihood ratio test
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ferences in clinical parameters between cp-LoViReT and controls
(Suppl. Table 1).
Total HIV-1 DNA was measured before cART and in several sam-
ples after initiation of cART (median: 4 [IQR 4-5] samples per individ-
ual) (Fig. 2a). All participants had detectable HIV-1 DNA before
therapy, thus minimizing technical primer-mismatch hybridization
issues. Fig. 2a shows the dynamics of total HIV-1 DNA in all the sam-
ples analysed. We observed a phase of faster decay during the first 18
months on cART, followed by a slower decay.
When we analysed the time points separately, we observed that
before initiation of cART, cp-LoViReT already harboured significantly
lower levels of HIV-1 DNA (p=0002) (Fig. 2b). The differences
observed before cART were independent from pVL, since no statisti-
cally significant differences were observed between the groups
(Suppl. Table 1).
After 18 months of treatment, a pronounced decline in HIV-1 DNA
was observed in all those studied, although median values were
lower in cp-LoViReT than in controls (p<0001). Finally, after 5 years
on cART, samples from both groups showed the greatest differences
within the study (p<0001). cp-LoViReT reached a median of 54 HIV-
1 DNA copies/106 CD4+ T cells, which is comparable to the values we
observed in the initial PBMC screening.
When we compared the decay in the HIV reservoir after 5 years
on cART with before cART, we observed a significantly greater
decrease in cp-LoViReT subjects than in controls (16- vs. 5-fold
respectively, p<0001) (Fig. 2c). In addition, a significant positive cor-
relation was observed between these 2 time points (rho=076,
p<0001) (Fig. 2d).
We observed that cp-LoViReT individuals had low viral reservoirs
before initiation of cART, as well as enhanced decay during
treatment.
Characterization of T-cell subsets, activation, exhaustion, and res-
ervoir surrogate markers: Immunophenotyping of T cells was per-
formed in the samples used for the longitudinal reservoir analysis. As
expected, we found a significant increase in the frequency of CD4+ T
cells and a significant decrease in the frequency of CD8+ T cells after
initiation of cART, thus leading to a significant recovery of the CD4/
CD8 T-cell ratio. No differences were observed between cp-LoViReT
and the control groups over time (data not shown).Analysis of maturation subsets in CD8+ T cells revealed the
expected significant increase in the frequency of TN cells after initia-
tion of therapy in both groups, with similar rates of increase; how-
ever, the frequency was higher at month 18 in cp-LoViReT than in
controls (p=0043) (Fig. 3a,b). Although we did not observe signifi-
cant differences between the groups in the frequency of TCM (Fig. 3c),
we did detect a lower frequency of TTM and TEMRA cells before initia-
tion of cART in cp-LoViReT than in controls (p=0011 for TTM and
p=0016 for TEMRA). This association disappeared when cART was
introduced (Fig. 3df). The correlation between HIV-DNA and these
cellular markers was assayed at each time point, although we did not
find statistically significant correlations (data not shown).
Activated (CD38+HLA-DR+) and PD-1+ CD8+ T cells decreased sig-
nificantly over time in both groups (Fig. 3g,h). However, no signifi-
cant differences between groups were observed. Values for the other
exhaustion markers analysed, TIM-3 and LAG-3, were similar in both
groups (Fig. 3i,j).
In CD4+ T cells, we did not observe any significant difference
between cp-LoViReT and controls over time in any T-cell maturation
subset (Suppl. Fig. 3a-f). Activation, defined as co-expression of
CD38+HLA-DR+, and PD-1 expression levels decreased overtime in both
groups with no intergroup differences (Suppl. Fig. 3g,h). Similarly, we
did not find significant intergroup differences in the reservoir surrogate
markers TIM-3+, CD2bright, CD32, and LAG-3+ (Suppl. Fig. 3il).
Additionally, immunophenotyping of NK cells was performed in
11 samples before initiation of cART and after 5 years on cART. In this
case, we analysed the frequencies of NK cells and their different acti-
vator/inhibitor receptors with a putative role in HIV control. No dif-
ferences were found between cp-LoViReT and controls in the
frequency of NK cells (Suppl. Fig. 4a) or in the expression of the C-
type lectin-like receptors (NKG2) (Suppl. Fig. 4b-e), killer immuno-
globulin-like receptors (KIR) (Suppl. Fig. 4f-g), activator natural cyto-
toxicity receptors (NCR) (Suppl. Fig. 4h-i), and CD161 (Fig Suppl. 4j).
However, a statistically significant decrease in CD69 and CXCR5 was
observed for cp-LoViReT once they started cART, with similar trends
observed in the controls (Suppl. Fig. 4k-l).
In summary, we observed changes in CD8+ T-cell maturation in
cp-LoViReT with higher levels of TN in combination with lower TTM
and TEMRA CD8+ T cells before initiation of cART. This observation was
not associated with changes in activation or exhaustion of CD8+ T
cells in this group.
Fig. 2. Longitudinal measure of total HIV-1 DNA in CD4+ T cells by ddPCR.
(a) Decay in total HIV-1 DNA before and after initiation of cART. The light grey box indicates the period under cART. (b) Box plot of total HIV-1 DNA at 3 different time points:
pre-cART, 18 months after initiation of cART, and 5 years after initiation of cART. (c) Fold change decay in the sample before initiation of treatment and after 5 years of cART. (d)
Spearman correlation for total HIV-1 DNA pre-cART and after 5 years of cART.
6 C. Galvez et al. / EBioMedicine 57 (2020) 1028303.3. CD4+ susceptibility and viral inhibition by CD8+ and NK cells
To evaluate the functionality of the T cells and NK cells in both
groups of individuals, we analysed the susceptibility of the target
cells to HIV-1 infection and viral inhibition by CD8 and NK cells in the
same samples as those used for NK immunophenotyping. Thus, we
selected 11 cp-LoViReT and 11 controls with available samples before
initiation of cART and after 5 years on cART. We pulsed autologous
CD4+ T cells from each individual with a laboratory-adapted R5- viral
strain for 7 days (Fig. 4a). We observed that CD4+ T cells from cp-
LoViReT and controls were susceptible to HIV-1 infection and thatthere were no significant differences between groups before initia-
tion of cART or after 5 years on cART.
Autologous CD8+ T cells were also tested to analyse the suppres-
sion of viral replication (Fig. 4b); no significant differences between
cp-LoViReT and controls were observed. High variability in the inhi-
bition percentage was recorded in all the samples assayed; this could
be explained by the limitation arising from the use of frozen cells in
this assay.
Similarly, we did not find significant differences in the percentage
of inhibition by autologous NK cells between groups before initiation
of treatment or after 5 years on cART (Fig. 4c).
Fig. 3. Analysis of maturation subsets, activation, exhaustion, and surrogate markers in the reservoir in CD8+ T cells.
(a) Median CD8+ T-cell values for the frequency of the maturation subsets (naïve, central memory, effector memory, transitional memory, and effector memory RA+) in controls
and cp-LoViReT at 3 different time points: pre-cART, 18 months after initiation of cART, and 5 years after initiation of cART. Maturation stages were defined based on the
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Fig. 4. CD4+ T cell susceptibility to HIV and viral inhibition by CD8+ T and NK cells.
PBMC samples before initiation of cART and after 5 years on cART were used to analyse the susceptibility of CD4+ T cells to HIV BaL (CCR5 tropic strain) (10 ng p24/ml) (a). We
also measured the ex vivo ability of CD8+ T cells (b) and NK cells (c) to inhibit superinfected autologous CD4+ T cells at a 1:1 ratio. The cp-LoViReT group is depicted in blue and the
control group in grey.
8 C. Galvez et al. / EBioMedicine 57 (2020) 102830CD4+ T cells from cp-LoViReT were perfectly susceptible to HIV
infection, with no signs of distinct CD8 and NK cytotoxic activities
compared with control individuals.
3.4. Inflammatory marker levels in cp-LoViReT
We measured soluble plasma pro-inflammatory or homeostatic
cytokines (IL-2, IL-6, IL-7, IL-10, IL-27, IP10) and the coagulation fac-
tor D-dimer in plasma samples from 8 cp-LoViReT and 9 controls
before cART and after 5 years on cART (selected according to sample
availability). We did not find statistically significant differences either
over time or between groups (Suppl. Table 2).combination of CD45RA, CD197 (CCR7), and CD27. (b) CD45RA+CD197+ (Naive), (c) CD45
CD45RACD197CD27+ (effector memory), and (f) CD45RA+CD197 (effector memory RA+).
cell exhaustion markers including PD-1 (CD279), TIM-3, and LAG-3. The cp-LoViReT group is
ences are depicted with a light blue or grey line for LoViReT and controls respectively; statist3.5. HIV-1 specific antibodies
To determine whether low reservoirs could be associated with
humoral responses to HIV-1, we analysed HIV-1-specific antibodies
in plasma samples before initiation of cART and after 5 years on cART
in 8 cp-LoViReT and 9 controls for whom plasma samples were avail-
able. We observed a decrease in HIV-1-specific antibody levels in
both groups after initiation of cART (Fig. 5a). This decay was greater
in cp-LoViReT than in controls (Fig. 5a).
We also measured the avidity of antibodies using a limiting anti-
gen avidity assay. We observed trend toward a more pronounced
reduction in antibody avidity in cp-LoViReT when cART was initiated,RACD197+ (central memory), (d) CD45RACD197CD27 (transitional memory), (e)
(g) CD8 activation levels (HLA-DR+CD38+) in both study groups over time. (h-j) CD8+ T-
depicted in blue and the control group in grey. Intragroup statistically significant differ-
ically significant differences between groups are depicted with a red line.
Fig. 5. Measurement of HIV-1-specific antibodies.
Plasma samples before initiation of cART and after 5 years of cART were tested for HIV-1-specific antibody levels using a detuned version of the HIV-1 VITROS assay (a) and a
limiting antigen avidity assay (b). The dotted line represents the HIV-1 antibody assay diagnostic cut-off level used to classify individuals as HIV-1-positive or -negative. The p-val-
ues between groups were assessed using the Mann-Whitney test.
C. Galvez et al. / EBioMedicine 57 (2020) 102830 9with most individual levels falling below the cut off seen in acute
HIV-1-infected subjects (Fig. 5b).
Therefore, HIV-1 antibody quantity and quality were more
markedly diminished upon initiation of cART in cp-LoViReT.4. Discussion
Latent infection of CD4+ T cells is established very early after infec-
tion and is the major obstacle to curing HIV-1 infection [28]. A low
HIV-1 DNA reservoir has been associated with early treatment [14]
and better clinical outcome [29]. Nevertheless, the size of the HIV-1
DNA reservoir is not necessarily associated with time to viral rebound
in subjects treated early after infection and who discontinued their
cART [16,29]. The global frequency of HIV-1-infected individuals har-
bouring low levels of HIV-1 DNA and the determinants of these levels
remain unknown.
In our study, we found that 93% of the individuals screened had
HIV-1 DNA levels below 50 copies/106 PBMCs (LoViReT subjects). The
proportion of LoViReT individuals was similar in the 2 recruiting
centres, indicating that our data might be extrapolated to other clini-
cal sites with similar subject populations and viral subtypes. Previous
studies in treated chronically infected individuals found that 28% and
19% of individuals had HIV-1 DNA levels below 150 copies/106 PBMCs
and 66 copies/106 PBMCs, respectively [18,19]. While both studies
revealed greater amounts of individuals with low HIV-1 DNA levels,
the differences observed with our results could be explained by their
higher cut-off for defining low HIV-1 DNA. Reanalysis of our dataset
after applying their cut-offs revealed that 33% and 19% of individuals,
respectively, had a “low reservoir”, thus confirming this hypothesis.
We maintained our cut-off of 50 copies/106 PBMCs because it repre-
sents the 10th percentile of the screened population.Various clinical parameters were associated with LoViReT status,
including a higher CD4+ nadir, lower maximum pVL, and fewer
detectable pVLs. Nevertheless, the model is not strong enough to
identify LoViReT individuals, suggesting that other viral or immuno-
logical factors might be involved. The same 3 factors have been found
to be closely associated with harbouring low levels of HIV-1 reservoir
[18,19,30,31], probably because a higher CD4+ T-cell nadir could pre-
vent repopulation of the immune system with expanded latently
infected lymphocytes. Moreover, a lower pVL peak might have pre-
vented massive seeding of CD4+ T cells by HIV-1. Similarly, fewer
detectable pVLs during the course of the infection might have pre-
vented replenishment of the reservoir.
Previous studies have reported the association between early
treatment and low viral reservoirs [14,32,33]. However, only individ-
uals treated in Fiebig I-IV (between 1 week and 1 month after infec-
tion) were capable of achieving low levels of total HIV-1 DNA after
more than 3 years on treatment [14,15]. Surprisingly, if early treat-
ment is excluded as the main cause of a remarkably low reservoir,
66% of the LoViReT subjects were treated more than 6 months after
acquisition of HIV-1 (cp-LoViReT). Since eradication strategies need
to be effective in the vast majority of treated chronically infected
individuals, it would be of considerable interest to know the mecha-
nism responsible for the low reservoir detected in this group of indi-
viduals.
Data on the kinetics of HIV-1 reservoirs have been reported in
treated chronically infected individuals [3436] harbouring standard
levels of total HIV-1 DNA or treated during primary infection [15,37].
However, to our knowledge, this is the first study to address the
kinetics of reservoirs in chronically HIV-1-infected individuals har-
bouring low levels of total HIV-1 DNA, including during the pre-cART
period. Our results provide the first evidence that cp-LoViReT have
intrinsically lower levels of total HIV-1 DNA before starting
10 C. Galvez et al. / EBioMedicine 57 (2020) 102830treatment, despite having the same levels of plasma viremia as con-
trols. Besides, once cART is introduced, their reservoir seems to be
more ART-sensitive, since decay of total HIV-1 DNA is faster in cp-
LoViReT. We also proved that their CD4+ T cells were susceptible to
infection; therefore, the low reservoir observed is probably due to
factors that do not severely impact the viral replication cycle in the
cells. Thus, we cannot exclude the possibility that cp-LoViReT might
have more linear unintegrated DNA, which decays faster than inte-
grated DNA in the presence of cART [38,39]. These parameters will be
analysed in future prospective studies. Additionally, and consistent
with other authors, we found a positive correlation between pre-
treatment levels of total HIV-1 DNA and levels after 5 years on cART,
thus demonstrating the importance of certain features before initia-
tion of cART, such as host factors and/or the immune system, in
determining subsequent reservoir size [17,40].
A naturally low level of cell-associated HIV-1 DNA could result in a
more preserved immune system. cp-LoViReT had fewer CD8+ TTM and
TEMRA in the absence of cART, with frequencies similar to those of
HIV-1-negative individuals, suggesting a less impaired CD8+ T-cell
compartment. HIV-1 infection disrupts T-cell subset homeostasis,
with a dramatic decrease in the frequency of CD8+ TN cells and mas-
sive expansion of CD8+ TTM cells in infected individuals treated during
both the acute phase and the chronic phase [41]. Furthermore, after
18 months on therapy, the differences in CD8+ TN cells between cp-
LoViReT and controls become statistically significant, with the result
that CD8+ TN cells were more numerous than in controls. The higher
proportion of CD8+ TN, also observed in elite controllers, may suggest
shared preservation of thymic function [42]. However, in LoViReT
individuals, the preserved CD8+ T-cell compartment does not seem to
be associated with an enhanced cytotoxic capacity of their CD8+ T
cells or NK cells, in contrast to HIV-1 controllers for CD8+ T cells [43]
and post-treatment controllers for NK cells [44]. Further exploration
with fresh cells, more participants, and assessment of the frequency
of HIV-specific cells will be needed to fully elucidate this point.
Finally, consistent with the kinetics of total HIV-1 DNA, the
marked decline in the quantity and avidity of HIV-1-specific antibod-
ies in cp-LoViReT during cART indicates a lower amount of circulating
HIV-1 antigen. Our findings are in line with results in treated chroni-
cally infected individuals from Keating et al [45], who reported an
association between declining antibody levels during cART and lower
levels of antigen production, better viral control, and lower systemic
viral burdens. cp-LoViReT represent a new phenotype of individuals
characterized by low intrinsic total HIV-1 DNA, better immune pres-
ervation, and low circulating HIV-1 antigens despite being treated in
the chronic phase of the infection. Levels of proviral DNA while on
cART in some individuals of the well-characterized post-treatment
and elite controller cohorts were as low as those of LoViReT individu-
als, with median levels of 1.7 and 1.5 log10 copies per million PBMCs,
respectively [46]; however, we can rule out an overlap between
cohorts. LoViReT had high viral loads during chronic infection before
initiation of treatment. This finding differs from the main factors
associated with elite and post-treatment controller cohorts. In addi-
tion, various studies suggest that having low amounts of HIV-1 DNA
does not prevent early and consistent viral rebound if therapy is
interrupted in infected individuals receiving long-term treatment
[20,47,48]. Therefore, a very low reservoir is not necessarily associ-
ated with spontaneous control of viral replication, as might be the
case in elite controllers or post-treatment controllers. However,
when attempting to identify combined approaches toward finding a
cure for HIV-1 infection, cp-LoViReT appear to be excellent research
participants, since they have better preserved immune cell popula-
tions and start from a smaller reservoir, which might be an advantage
over individuals with a larger reservoir.
Our study was subject to a series of limitations. HIV-1 DNA was
only measured in peripheral blood, whereas larger HIV-1 reservoirs
are known to be found in lymph nodes and gut-associated lymphoidtissues. However, as this was a retrospective analysis, it was not pos-
sible to have access to those samples. The full size of the HIV-1 reser-
voir was only evaluated in total HIV-1 DNA, thus enabling all forms of
cellular HIV-1 DNA (unintegrated linear, 1-LTR and 2-LTR circular
forms, and integrated forms) to be quantified. Other methods of
studying the HIV reservoir, such as assessment of replication-compe-
tent or -defective virions and quantification of the inducible reservoir
at the RNA level, could prove useful. However, the quantification of
replicative or intact virus in individuals with very low viral reservoirs
might be challenging, since they represent less than 10% of total HIV-
DNA [49].
In addition, we were unable to identify a molecular mechanism
that could explain the limited reservoir in LoViReT individuals. Future
research will be needed to unravel whether this cohort shares a com-
mon molecular mechanism that decreases the ability of the virus to
establish latency.
In conclusion, we found that some HIV-1-infected individuals
have low levels of total HIV-1 DNA (LoViReT subjects) and that most
were treated in the chronic phase of the infection. Moreover, they
have a less compromised CD8+ T-cell compartment and lower HIV-1-
specific antibody levels, probably as a result of lower amounts of cir-
culating antigens. Among those who started treatment in the chronic
phase, these are perfect candidates for the study of combined
approaches to finding a cure for HIV-1, since we proved that cp-
LoViReT are characterized by a viral reservoir that is intrinsically
reduced before initiation of cART and enhanced decay after initiation
of treatment.
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